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Calcific aortic valve disease (CAVD) is the most frequent heart valve disorder. It is
characterized by an active remodeling process accompanied with valve mineralization,
that results in a progressive aortic valve narrowing, significant restriction of the valvular
area, and impairment of blood flow.The pathophysiology of CAVD is a multifaceted
process, involving genetic factors, chronic inflammation, lipid deposition, and valve
mineralization. Mineralization is strictly related to the inflammatory process in which
both, innate, and adaptive immunity are involved. The underlying pathophysiological
pathways that go from inflammation to calcification and, finally lead to severe stenosis,
remain, however, incompletely understood. Histopathological studies are limited to
patients with severe CAVD and no samples are available for longitudinal studies of
disease progression. Therefore, alternative routes should be explored to investigate the
pathogenesis and progression of CAVD.Recently, increasing evidence suggests that
epigenetic markers such as non-coding RNAs are implicated in the landscape of
phenotypical changes occurring in CAVD. Furthermore, the microbiome, an essential
player in several diseases, including the cardiovascular ones, has recently been linked to
the inflammation process occurring in CAVD. In the present review, we analyze and
discuss the CAVD pathophysiology and future therapeutic strategies, focusing on the real
and putative role of inflammation, calcification, and microbiome.
Keywords: severe aortic stenosis, calcific aortic valve, aortic valve replacement, TAVR, microbiome, immune
system, inflammationin.org May 2020 | Volume 11 | Article 6851
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Calcific aortic valve disease (CAVD) is the most common valve
disease worldwide (Nkomo et al., 2006). Epidemiological studies
show that 2.8% of adults over 75 years old have some CAVD
degree, and as many as 25% of adults over 65 years old have at
least valvular sclerosis (Miller et al., 2011).
CAVD is a chronic process characterized by progressive
fibrotic tissue remodeling and mineralization (Mathieu et al.,
2015). Over the years, there is a disease continuum from sclerosis
to chronic inflammation and finally leaflet calcification,
culminating with severe stenosis. Human pathologic samples
have shown that key features in the CAVD development include
pathological concentrations of inflammatory cells and lipid
species (Otto et al., 1994; O’Brien et al., 1996).
Several risk factors have been identified as relevant in the
CAVD progression. Among others, male gender, high
triglyceride levels, and smoking have been independently
associated with early aortic valve replacement in the presence
of CAVD. Levels of oxidative stress, higher in patients that are
more exposed to certain risk factors than others, could be
responsible for the starting of the sclerotic CAVD phase
(O’Brien, 2006; Ferreira-Gonzalez et al., 2013).
Calcification is recognized as an active disease process driven
by the native valvular interstitial cells (VICs) (Sun et al., 2013).
These cells acquire an osteogenic and pro-calcific profile in
response to different pathological st imuli , such as
inflammatory mediators, endothelial damage, low-density
lipoprotein (LDL) accumulation, reactive oxygen species
(ROS), increase calcium/phosphate (Ca/Pi) levels, modified
lipids, and cyclic stretch (Liao et al., 2008; Rajamannan et al.,
2011; Rattazzi et al., 2014). The underlying process that ends
with the ectopic mineralization of the aortic valve is still not
entirely understood. Treatment options include operative valveFrontiers in Pharmacology | www.frontiersin.org 2replacement and percutaneous implantation of valve prosthesis
(Lauten et al., 2013; Lauten et al., 2014; Daubert et al., 2016;
Alushi et al., 2019; Wernly et al., 2019).
To date, there is no medical treatment available to prevent or
reverse calcium deposition within the valve leaflets. Conventional
cardiovascular drugs studied in clinical trials failed to influence
the disease progression or reduce adverse outcomes, therefore
additional research is required to understand the mechanisms of
disease progression and, identify novel therapeutic targets
(Cowell et al., 2005; Freeman and Otto, 2005; Rossebo et al.,
2008; Chan et al., 2010).CAVD BIOLOGY
Histological Structure of the Aortic Valve
The aortic heart valve consists of three leaflets that allow blood
flow from the left ventricle to the aorta without regurgitation
(Liao et al., 2008). Each leaflet has a trilaminar structure that is
vital for the biomechanical properties of the aortic valve (Tseng
and Grande-Allen, 2011; Lindman et al., 2016) as shown in
Figure 1. Histologically, the leaflets are composed of three
distinct layers: fibrosa, spongiosa, and ventricularis. Fibrosa
and ventricularis are the external layers, facing the aorta and
the left ventricle respectively. Fibrosa consists largely of collagen
fibers with dispersed VICs, that are thought to be responsible for
reinforcing the valvular structure (Dweck et al., 2012a).
The central layer, spongiosa, is rich in glycosaminoglycans
(GAGs) and is responsible for absorbing some of the mechanical
stress generated during the cardiac cycle.
The ventricularis is localized on the ventricular side of the
leaflets and consists of collagen and elastin fibers (Chen and
Simmons, 2011; Mathieu et al., 2015). The tissue composition of
ventricularis provides more compliance and grants theFIGURE 1 | Histological structure of the aortic valve. Depicted is the histological structure of the healthy aortic valve. Fibrosa, spongiosa, and, ventricularis are the
three layers that make up the structure of a normal aortic valve. The Fibrosa layer is composed of type I and III collagen fibers and contains also VICs. Spongiosa
and ventricularis layers are respectively composed of GAG and proteoglycans and elastin fibers. Endothelial cells form a monolayer on each side of the cusp. GAG,
glycosaminoglycans; VIC, valve interstitial cell.May 2020 | Volume 11 | Article 685
Alushi et al. CAVD Development and Future Perspectivesapposition of free edge leaflet regions, thus preventing the
backward blood flow into the left ventricle during diastole
(Lindman et al., 2016). The normal valve leaflet is avascular
and free of infiltrating lymphocytes or monocytes.
Pathobiology of CAVD
The CAVD pathophysiology is schematically depicted in
Figure 2. The process of progressive fibrocalcific remodeling of
the aortic valve is multifactorial, involving genetic predisposition,
endothelial shear stress, chronic inflammation, lipid deposition,
and valve calcification (Freeman and Otto, 2005; Perrot et al.,
2019; Thériault et al., 2019). In its early stages, CAVD resembles
atherosclerosis. The existence of shared risk factors for the
disease development and the correlation between the severity
of CAVD and that of coronary calcification suggest a shared
disease pathway, at least in the initial phases of both diseases.
Alike atherosclerosis, the triggering event in CAVD is
endothelial damage resulting from increased mechanical stress
and reduced shear stress. Physiologic fluid shear stress (FSS)
contributes to valve homeostasis, whereas altered shear stress, on
the contrary, stimulates the endothelial upregulation of vascular
cell adhesion molecule-1 (VCAM-1) and intracellular adhesion
molecule-1 (ICAM-1) (Sucosky et al., 2009; Sun et al., 2013). The
endothelial damage following the altered shear stress allows the
infiltration of lipids, especially LDL and lipoprotein (a) [Lp(a)],
starting the recruitment of inflammatory cells into the leaflets.
Later appears the formation of focal subendothelial plaque-like
lesions constituted from LDL, Lp(a) and infiltrates of
inflammatory cells which interact in processes that release ROSFrontiers in Pharmacology | www.frontiersin.org 3causing LDL oxidation. In time, the expansion of this
inflammatory process triggers the release of factors that cause
VICs to acquire an osteogenic profile, with the formation of
microcalcifications initiating leaflet mineralization (Otto et al.,
1994; O’Brien et al., 1996). The two disease processes differ in the
later disease phases: while in atherosclerosis, smooth muscle cells
are the active players in the chronic inflammation within the
plaque, in CAVD fibroblasts are involved in the prominent
mineralization process and only with a small number of
smooth muscle cells is present.
The hallmark of the early CAVD stages is inflammation,
characterized by the activation of the leaflet endothelium via
enhanced expression of cell adhesion molecules (VCAM-1,
ICAM-1) (Sun et al., 2013; de Sousa et al., 2017). Disease
initiation involves the activation of VICs, recruitment of
immune cells, and subsequent sclerosis of the valve leaflets
owing to fibrosis and formation of calcific nodules. All these
phenomena start and interest more the fibrosa layer within the
valve. The first macroscopic change in the leaflets, seen as
microcalcifications, or focal thickening with preserved valve
function, is nominated aortic valve sclerosis, nonetheless, the
initiating events likely occur much earlier. The activation degree
of the immune system seems to be different on different
examined valve areas. Interestingly, the thickening process and
the formation of calcium nodules accompanied by neo-
angiogenesis, are both localized near the aortic surface of the
leaflets (Cote et al., 2013).
The final disease, namely calcific aortic stenosis, is
characterized by large calcified noduli on the leaflet surface,FIGURE 2 | CAVD development. Depicted is the pathophysiologic cascade leading to CAVD. Initial lesions, such as mechanical stress, endothelial damage and,
production of ROS, initiate an ox-LDL-mediated inflammation in the endothelium and promote the activation of macrophages and quiescent VICs. These start to
express TLRs and the cytokine pro -inflammatory IL-6, which plays a fundamental role in inflammation, together with macrophages and T cells. IL-6 mediates
mineralization through the BMP-2 signal, driving the osteogenic transition and culminating with the aortic valve calcification. CAVD, calcific aortic valve disease; GAG,
glycosaminoglycans; IL-6, interleukin 6; Lp(a), lipoprotein a; ox-LDL, oxidized low-density lipoprotein; ROS, reactive oxygen species; TLRs, toll-like receptors, VECs,
valve endothelial cells; VICs, vascular interstitial cells, BMP-2, bone morphogenetic protein 2.May 2020 | Volume 11 | Article 685
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mobility (Rajamannan et al., 2011). In this final phase the leaflets
are infiltrated by immune cells and concomitantly angiogenesis
occurs, along with deposition of lipids, proteoglycans, and cell
debris (Chen and Simmons, 2011). Finally, the calcification of
the valvular matrix leads to an increased stiffness and obstruction
of the blood flow (Figure 2). With an orifice under 1 cm2, versus
2.5–4.5 cm2 observed in a normal valve, the stenotic valve
generates a pressure gradient of over 40 mmHg, categorized as
severe stenosis with an indication to valve replacement
(Zigelman and Edelstein, 2009; Rutkovskiy et al., 2017).
Impact of Inflammation in CAVD Remodeling
Inflammation is the primary response of innate immunity and
occurs after endothelial damage with its activation and lipid
deposition. The innate immune response, with both its
components, cellular and humoral responses are implicated in
this process. As response to an injury induced by foreign
organisms, dead cells or physical irritants, the innate immune
system represents the first response to external or internal
triggers and initiates the process of tissue regeneration (Hulin
et al., 2018; De Almeida et al., 2019). Once the inflammation
process has been triggered, it will proceed along a certain course
of events until the inflammatory stimulus is eradicated and the
healing mechanism can begin. However, if the inflammatory
source cannot be eliminated, inflammation will progress, varying
in intensity over time (Hakansson and Molin, 2011).
Histological samples of human CAVD valves are
characterized by calcified areas rich in lymphocytes,
macrophages, and osteoblast-like cells (Hulin et al., 2018). The
inflammatory process can be acute or chronic (Pahwa and Jialal,
2019). Cote´ et al. showed that chronic inflammatory infiltrates,
composed of the CD45+ leukocytes, CD68+ macrophages, and a
few scattered CD3+ T cells, were present near the calcified areas.
Moreover, the chronic inflammatory infiltrates in the aortic valve
were independently associated with several indices of
remodeling, suggesting that inflammation may participate in
mineralization and the fibrotic process (Cote et al., 2013). A
significant association between the degree of aortic valve
inflammation and the development of calcification has been
previously reported (and recently confirmed) using 18F-
fluorodeoxyglucose positron emission tomography. In these
studies, a high degree of inflammation and calcification was
documented in patients with severe CAVD, with the latter being
the predominant pathogenic process (Marincheva-Savcheva
et al., 2011; New and Aikawa, 2011; Dweck et al., 2012b). This
could in part explain the failure of statin therapy in slowing the
CAVD progression (Cowell et al., 2005; Rossebo et al., 2008).
Previously thought to be a passive disorder, CAVD is now
recognized as an active process, whereby endothelial progenitor
cells (EPCs) and inflammatory cells promote tissue remodeling
(Yip and Simmons, 2011). In summary, mechanical shear stress
and atherogenic factors activate VICs and initiate the
recruitment of inflammatory cells. The following remodeling of
extracellular matrix with leaflet stiffening and valvular
dysfunction causes further mechanical stress that maintains the
self-perpetuating cycle of endothelial dysfunction. As suggestedFrontiers in Pharmacology | www.frontiersin.org 4by studies with molecular imaging, the continuous maintenance
of this shear stress-inflammation cycle could result irreversibly to
calcium deposition and finally to severe CAVD (New and
Aikawa, 2011).
Role of Lipids
Over recent years, several studies have highlighted the central
role of ox-LDL as an activator of inflammation, both in
atherosclerosis and in CAVD (Cote et al., 2008). In
atherosclerotic plaques, ox-LDL activates the inflammatory
cells and the production of cytokines promoting tissue
remodeling and disease progression (Hansson, 2005). Existing
evidence of valve infiltration by ox-LDL in cases of CAVD,
supports the concept that the development of valve calcification
may be, at least in part, influenced by ox-LDL and, that an
association exists between high plasma levels of ox-LDL and
CAVD (Mohty et al., 2008). Although having some similarities
with atherosclerosis, CAVD differs from it since the aortic valve
has some inherent properties that differ from the vascular wall.
Indeed, the cellular organization, as well as the hemodynamic
stress imposed upon the aortic valve, vary from that of the
arteries. Furthermore, the phases that characterize the
pathological process occurring within the valve, from early
inflammation stages to the calcification ones, are more
numerous and qualitatively different from atherosclerosis, as
shown in Figure 2. Most importantly, statins, although
efficient in reducing adverse events in patients with
atherosclerosis, are inefficient in CAVD (Cowell et al., 2005;
Rossebo et al., 2008; Chan et al., 2010).
Role of the Immune Response in CAVD
The immune system, with innate and adaptive responses, plays a
central role in the development of different chronic disorders,
including atherosclerosis and CAVD. Evidence suggests that
inflammation, as the primary response of the innate immunity,
promotes the mineralization of VICs in response to several
factors. Adaptive immunity, on the other hand, could play a
role in instrumenting the immune response (Cote et al., 2013). In
this regard, experimental studies have shown that the increased
leukocyte density in mineralized aortic valves correlates with
faster disease progression (Mathieu et al., 2015).
Innate Response in CAVD
The innate immune response in CAVD |+|}_–be initially
triggered by several oxidized lipid species, through both the
toll-like receptors (TLRs) and the nuclear factor-k B (NF-kB)
pathway. VICs express TLRs, known to play a key role in
inflammation and initiation of antigen-specific adaptive
immune responses. TLRs can be activated by several lipid
species, especially ox-LDL, with the signal passing through the
recruitment of specific adaptor molecules to the activation of the
transcription factor NF-kB (Kawasaki and Kawai, 2014; Garcia-
Rodriguez et al., 2018). In this way, TLRs signal inflammation
through the NF-kB pathway and are vital for maintaining
tissue homeostasis.
NF-Kappa B Pathway. The NF-kB plays an important role in
signal integration by responding to mediators of endothelialMay 2020 | Volume 11 | Article 685
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tion by producing a high level of cytokines, and the NF-kB
pathway contributes to a stimulus-dependent and cell-type-
specific manner. The NF-kB activation (canonical and non-
canonical) pathway is mediated by different extracellular signals
including angiotensin II, ox-LDL, CD40 ligand, advanced
glycation end-products, and inflammatory cytokines. The
canonic pathway is activated, among others, by tumor necrosis
factor alpha (TNF-a) and interleukin-1b (IL-1b). Angiotensin
II-induced ROS generated also on mineralized aortic valves, are
involved in the activation of the NF-kB canonic pathway
(Jamaluddin et al., 2007). The non-canonical pathway is acti-
vated, among others, by vasoactive peptides, ox-LDL, activated
CD40 receptor, B cell-activating factor (BAFF), lymphotoxin b
(LTb) monocyte released cytokines, or advanced glycation end-
products (Xiao et al., 2004; Morrison et al., 2005). In summary,
activated NF-kB controls the initiation of vascular inflammation,
through “leucocyte adherence” and “chemotaxis” and is a crucial
signaling integrator of vascular injury.
Cytokines. One important target of the NF-kB pathway is IL-6.
Highly expressed in valves with severe CAVD, IL-6 is a pleio-
tropic cytokine secreted by multiple vascular cell types, such as
macrophages, lymphocytes, fibroblasts, endothelial cells, and
smooth muscle cells. It mediates local vascular monocyte acti-
vation and protection from ROS-induced cellular stress via the
downstream transcription effector signal transducer and activa-
tor of transcription 3 (STAT3) (Brasier, 2010; El Husseini et al.,
2014; Rahat et al., 2016; Huang et al., 2019). By controlling the
monocyte activation vial the IL-6 pathway, NF-kB mediates
the systemic acute phase response and plays a central role in the
initiation and maintaining of the vascular inflammation (Brasier,
2010; Perez et al., 2019).
IL-1b is another intriguing cytokine involved in the valve
calcification process. Its levels are indeed increased in the stenotic
aortic valve, making IL-1b subject to numerous research studies in
the last decade (Isoda et al., 2010; Nadlonek et al., 2013; Lee and
Choi, 2018). The IL-1b enhances the expression of matrix
metalloproteinases (MMPs), a group of enzymes responsible for
the degradation of extracellular matrix proteins. The MMPs
exacerbate the process of valvular stenosis and activate the NF-kB
pathway, leading to the production of several cytokines, such as IL-
6, IL-8, and MCP-1 (monocyte chemoattractant protein-1)
involved in both pathological processes, namely atherosclerosis
and CAVD (Deshmane et al., 2009).
Finally, the IL-1 receptor agonist (IL-1Ra) plays a protective
role in valvular disease, as its deficiency is closely associated with
inflammatory cell infiltration and valve thickening (Isoda et al.,
2010). Using in vitro and in vivo models, Zeng et al. elucidated
the role of IL-37, an anti-inflammatory member of the IL-1
family. IL-37 attenuates the expression of bone morphogenetic
protein 2 (BMP2) and alkaline phosphatase (ALP) enzyme,
inhibiting the osteogenic process. In CAVD, the expression
levels of IL-37 are very low, consequently, BMP2 is free to
promote VICs calcification by ALP expression leading
subsequently to aortic valvular thickening. Confirming the
protective role of IL-37, in vivo experiments showed that miceFrontiers in Pharmacology | www.frontiersin.org 5expressing this human cytokine, displays significantly lower
BMP-2 levels and a lower degree of aortic valve thickening
(Zeng et al., 2017).
Adaptive Response in CAVD
The key role of lymphocytes in CAVD and the presence of T-
lymphocyte clonal expansion in stenotic valves has been
highlighted by various studies (Wallby et al., 2002; Mazzone
et al., 2004; Mazur et al., 2018). In a study involving patients with
severe CAVD, Wu et al. observed the presence of CD8 +/CD28−
T cells near the mineralized nodules of the aortic valve and a
higher prevalence of circulating CD3+ T cells, namely the subset
of CD8+ and CD57+ T cells expressing HLA-DR, in subjects with
CAVD (Wu et al., 2007). CD8+/CD28− T cells play a crucial role
in CAVD, as demonstrated by the correlation between the degree
of clonal expansion and the severity of valve calcification.
Furthermore, these cells play a crucial role in both activation
and differentiation of memory effector status among circulating
T cells. Winchester et al., investigated the composition of the
lymphocytic infiltration in patients with (bi-and tri-cuspid
CAVD). They showed an aggregate of infiltrating lymphocytes
containing CD4+ and CD8+ T cells, with a preponderance of
CD4 T cells. The clones shared between blood and the valve were
found in the memory-effector CD8+CD28− T cell subset,
demonstrating the trafficking of members of the same T cell
clone between the peripheral circulation and the valve.
Importantly, the proportion of activation of peripheral blood
T-lymphocytes strongly correlated with the degree of valve
calcification, indicating that the extent of these events is
somehow related to CAVD severity (Winchester et al., 2011).
This data suggests that in patients with CAVD, an adaptive
systemic immune response is occurring, coupled with the
valvular lymphocytic infiltration, probably triggered by
recognition of antigens expressed in the valve. The valvular
events that lead to an immune response, such as intracellular
pathogens, or self-antigens, remain unclear. One hypothesis is
that in response to shear stress the VICs express stress-induced
molecules which could be perceived as antigens and generate an
immune response.
Mineralization
At some point during the CAVD progression, VICs start to
produce a calcified matrix and enter an osteogenic phase. The
mechanisms of this switch are still poorly understood. One
hypothetical pathway involves IL-6 and the tumor necrosis
factor ligand superfamily member 11 (also called receptor
activator of NF-kB ligand—RANKL). IL-6 has been shown to
induce the expression of RANKL in bone cells, which activates its
cognate receptor RANK that finally activates VICs to produce
extracellular matrix and might therefore promote matrix
calcification (Wada et al., 2006). This could be a hypothetical
pathway, which through IL-6-RANKL overexpression promotes
the osteogenic reprogramming of VICs (Kaden et al., 2004).
Another pathway involving the expression of BMP2 via
inflammatory cytokines and oxidized lipid derivatives was
shown to induce osteogenic reprogramming in several cell
types including VICs (Shao et al., 2005).May 2020 | Volume 11 | Article 685
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Numerous genetic factors are implicated in the CAVD
pathogenesis (LaHaye et al., 2014). Two recent genome-wide
association (GWAS) studies showed that a genetic variation in
the LPA locus, mediated by levels of Lp(a), is involved in both
atherosclerotic disease and CAVD and that several pathways are
shared by both conditions. Lp(a) and non-high-density
lipoprotein cholesterol as shared risk factors contributed to the
frequent co-existence of these disorders (Thanassoulis et al.,
2013; Helgadottir et al., 2018).
A recent transcriptome-wide association study (TWAS)
identified PALMD (palmdelphin), a gene that promotes myoblast
differentiationandmuscle regeneration, as anadditionalkeygene in
CAVD.The study showedthat loweredexpression levelsofPALMD
mRNAinvalve tissues are associatedwith risk alleles forCAVDand
higher disease severity (Nie et al., 2017; Theriault et al., 2018).
Recently, Theriault et al. identified some additional susceptibility
genes in patients with CAVD. Using both techniques, GWAS and
TWAS, IL-6, ALPL (alkaline phosphatase), and NAV1 (neuron
navigator 1) emerged as important contributors involved not only
in pulse and blood pressure modulation—two important factors
associated with blood flow turbulence, already identified as risk
factors for CAVD development—but also in the valve
mineralization process. Moreover, the ALPL gene codes for
tissue-nonspecific alkaline phosphatase, a crucial enzyme
involved in mineralization. This gene was present in calcified
aortic valves contrary to non-calcified valves (Thériault et al., 2019).
All these findings taken together constitute a new step toward the
further elucidation of the CAVD pathogenesis and may open new
paths for the development of innovative therapeutic approaches.
Gender as a Risk Factor for CAVD
The role of gender as a biological variable, especially that of the
male sex as a risk factor for cardiovascular diseases, including
CAVD, has been long established (Carroll et al., 1992; Institute of
Medicine Board on Population H and Public Health P, 2012).
However, data regarding the significance of male sex in CAVD is
lacking. Indeed, most studies addressing sex-specific differences
in CAVD focus on conditions caused by CAVD, such as
ventricular dysfunction, rather than CAVD itself (Dobson
et al., 2016). It is mostly unclear whether the onset and
progression of CAVD are inherently different in men and
women, due to genetic and cellular-scale sex differences, or
whether the initial disease process is common in both sexes
but undergoes subsequent differentiation after (Porras et al.,
2017). Aggarwal et al. reported that male gender correlates
with an higher incidence of CAVD, as men displayed higher
levels of calcification for the same degree of aortic stenosis when
compared to women (Aggarwal et al., 2013). Another study
showed significant differences between stenotic valves in males
and females, where the latter were more prone to fibrosis.
(Sharma and Eghbali, 2014) Evidence points towards genetic
and epigenetic differences, specifically the differential production
of miRNAs, being the origin of these sex-specific differences
(Sharma and Eghbali, 2014).Frontiers in Pharmacology | www.frontiersin.org 6Epigenetic Regulation of CAVD
The remarkable developments in the field of epigenetics could
offer answers regarding the link between environmental and
proatherogenic factors, induction and perpetuation of
inflammation, and CAVD development. The four major
epigenetic mechanisms, collectively known as “epigenome”,
include non-coding regulatory RNAs (ncRNA), DNA
methylation, histone modifications, and chromatin remodeling
(Murr, 2010). Studying the link between epigenome and CAVD
could be clinically relevant since epigenetic markers could
represent non-invasive biomarkers for monitoring CAVD
initiation and progression and predicting prognosis.
ncRNAs, a group of single-stranded cellular RNAs made up
of 18–25 nucleotides, represent a new area of interest in the field
of human biology. These molecules, normally not coding for
proteins, were previously regarded as “dark matter” since their
function was largely unknown. Increasingly discovered to play a
central role in the regulation of various molecular pathways and
cell differentiation, ncRNAs are categorized in short, medium, or
long (lncRNAs) based on their transcript size (Aryal et al., 2014).
MicroRNAs (miRNAs) are the most well-studied ncRNAs,
involved in cell development, proliferation, lipid metabolism,
cancer metabolism, and angiogenesis (Palazzo and Lee, 2015).
They regulate gene expression after transcription, by
translational repression or transcript degradation. The role of
miRNAs and especially lncRNAs in regulating atherosclerotic
processes has been investigated in several studies suggesting that
some miRNAs may be important inducers of proinflammatory
pathways and others stimulators or inhibitors of calcification in
the human aortic VICs (Gosev et al., 2017). Among others,
miRNA-30b, miRNA-138, and miRNA-204 can suppress the
differentiation of mesenchymal cells into osteoblasts whereas
miRNA-29b and miRNA-214 promote calcification (Zhang
et al., 2014; Wang et al., 2015; Fang et al., 2018; Lu et al., 2019;
Zheng et al., 2019). miRNA-138 was indicated as a suppressor of
osteoblastic differentiation of human aortic VICs by targeting
FOXC1, representing, therefore, an inhibitor of VIC osteogenic
differentiation during the development of CAVD (Lu et al.,
2019). In 2017, the role of miRNA-29b as a promoter of
valvular calcification, through the TGF-ß3/Smad3 and wnt3/ß-
catenin pathways was reported (Fang et al., 2018) whereas in
2019, miRNA-214 was identified as a promoter of the human
aortic VICs calcification by accelerating inflammatory chain
reactions through MyD88/NF-kB signaling (Zheng et al., 2019).
Another epigenetic mark, the alteration of DNA methylation,
could have a role in the osteogenic differentiation of aortic VICs
by downregulating Notch/drosophila/homolog 1/translocation-
associated (NOTCH1), a regulator of calcification-related gene
networks in human valvular endothelium (Theodoris et al., 2015;
Hadji et al., 2016). Markers of histone modification have also
been reported to have a pro-inflammatory and osteogenic role in
CAVD development. They participate in the shear-stress
induced proinflammatory pathways via alteration of the silent
information regulator-two (SIRT) gene expression (Roos
et al., 2014).May 2020 | Volume 11 | Article 685
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epigenetic factors as regulators of key processes underlying
valvular tissue remodeling and participators in the landscape of
phenotypical changes occurring in CAVD. Understanding the
epigenetic mechanisms involved in the initiation and progression
of CAVD will not only help to enlighten the pathology, but since
these markers are potentially reversible, it could offer important
targets for diagnostic and therapeutic interventions.THE PUTATIVE ROLE OF THE
MICROBIOME
Herein we hypothesize a putative role of the microbiome in the
development and progression of CAVD, either via stimulation of
immune response and valve calcification or via direct valvular
damage caused by specific bacterial taxa. Different hints point to
a role microbiome in the promotion of CAVD and its
deterioration to severe calcified aortic stenosis. Some known
risk factors for CAVD, such as age, male sex, hypertension, and
diabetes mellitus, have a known relationship to the microbiome.
In fact, patients with type II diabetes mellitus (T2DM), which is
associated with the gut microbiota dysbiosis, are at higher risk for
developing CAVD (Harsch and Konturek, 2018). Tissue
histopathological studies demonstrated more calcification in
tissue samples from patients with T2DM compared to non-
diabetic patients (Mosch et al., 2017). Furthermore, the presence
of metabolic syndrome is associated with faster disease
progression and worse outcome in patients with aortic stenosis
(Katz et al., 2009). Here we discuss in detail the involvement of
oral and gut microbiome (GM) in pathophysiological processes
that promote cardiovascular diseases, including CAVD.
Oral Microbiome
The oral microbiome represents, after the GM, the second-
largest microbial community in humans and plays a
fundamental role in maintaining the oral cavity homeostasis
and preventing the development of several diseases (Jia et al.,
2018; Deo and Deshmukh, 2019). The involvement of the oral
microbiome in pathologies such as obesity, diabetes, cancer, and
cardiovascular diseases is well documented (Gao et al., 2016;
Eberhard et al., 2017; Long et al., 2017; Yang et al., 2019).
Different studies suggest that oral pathologies with oral
microbiome alteration, have a tight link with heart diseases; for
example, the gingival ulceration in periodontitis causes
bacteremia and could induce the formation of atherosclerotic
plaques (DeStefano et al., 1993; Bartova et al., 2014). Increasing
evidence suggests a close association between oral microbiome
alteration and CAVD, demonstrating the presence of oral
bacteria in the valvular tissue by using a polymerase chain
reaction (PCR) (Nakano et al., 2006). Nomura et al.,
investigated the mechanisms through which Streptococcus
mutans (S. mutants), the major pathogen responsible for
dental caries, colonizes heart valves constituting a potential
virulence factor for the development of infective endocarditis.
They demonstrated that specific strains of S. mutants haveFrontiers in Pharmacology | www.frontiersin.org 7selective virulence for infectious endocarditis (Nomura et al.,
2014; Oliveira et al., 2015). There is an increasingly accepted
hypothesis that bacterial endocarditis is one of the causes of
aortic valve calcification, supported by in vivo studies showing
larger calcifications in animals inoculated with endocarditis-
related pathogens.(Cohen et al., 2004)
Gut Microbiome
The composition of the human microbiome is specific to each
individual and the study of the GM is increasingly focusing on its
role in the physiology of the host organism in during phases of
health and disease (Blander et al., 2017). Changes in the
composition of GM are involved in several diseases including
atherosclerosis, hypertension, heart failure, chronic kidney
disease, obesity, diabetes, inflammatory bowel disease, and
colon cancer (Amedei and Barcelo-Coblijn, 2019). Growing
evidence suggests that intestinal bacteria play an essential role
in cardiovascular diseases. GM metabolites such as choline,
betaine, and trimethylamine N-oxide (TMAO), are the subject
of research studies investigating the correlation between the
intestinal microbiome and the calcification of the aortic valve.
Diets based on red meat, eggs, and dairy products are rich in
choline, lecithin, and carnitine, constituting, therefore, a
potential source of TMAO. Recent metabolomic studies
indicate that fasting TMAO, choline, and phosphatidylcholine
plasma levels are related to high risk of cardiovascular diseases.
Furthermore, carnitine has been indicated as an independent
predictor of major adverse cardiovascular events, with TMAO as
the main driver behind the risk association (Velasquez et al.,
2016; Canyelles et al., 2018). The idea that gut microbiota could
contribute to CAVD is new. Very recently Kocyigit et al. reported
a significant association between gut microbiota metabolites and
CAVD (Kocyigit et al., 2017) whereas Liu et al. showed that
patients with CAVD and those with coronary artery disease
suffer from different gut microbial dysbiosis (Liu et al., 2019).
The next section discusses the putative link between the GM and
CAVD development.
The Role of the GM in Adaptive Immunity
Several studies indicate a very close connection between the GM
and adaptive immunity. Bacterial metabolites function as a link
between the commensal microbiome and the immune system, by
affecting the shifting of the immune response between pro- and
anti-inflammatory pathways. Hypothetically, the gap between
the microbiome and immune system could be filled by short-
chain fatty acids (SCFAs), generated by bacterial fermentation of
dietary fiber in the intestinal lumen (Russo et al., 2016). SCFAs
such as acetate, propionate, and butyrate act as important
inductors of regulatory T (Treg) cell differentiation and
reinforce the gut barrier function by expressing the
transcription factor Foxp3 and consequently suppressing
inflammatory responses in the intestine (Arpaia et al., 2013). A
diet rich in SCFAs might antagonize several immunological
defects, therefore GM-derived metabolites could offer a
therapeutic advantage for patients suffering from various
immunological conditions (Luu et al., 2019).May 2020 | Volume 11 | Article 685
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cytokine responses and specific gut bacterial species were
identified through the Human Functional Genomics Project.
For instance, the production of interferon-g (IFN-g) and TNF-
a is strongly associated with the GM (Schirmer et al., 2016). The
fermentation of bacterial SCFAs acts through activation of G-
protein coupled receptors by modulating the activity of intestinal
epithelial cells and leukocyte life cycle. Furthermore, due to their
direct effect on lymphocytes and by activating macrophages and
dendric cells, SCFAs can induce a T-lymphocyte tolerogenic
profile, acting as a link between the microbiome and the immune
system (Correa-Oliveira et al., 2016).
In summary, the role of adaptive immunity in CAVD has
been explored, but the valvular events that lead to an immune
response, such as intracellular pathogens or self-antigens, remain
largely undetermined. Alike atherosclerosis, one could
hypothesize that the presence of a certain type of gut or mouth
microbiome could lead to the presence of bacterial DNA
inducing valvular specific antigens that could trigger an
immune response. The putative interaction between the
microbiome and immune response leading to CAVD
development is schematized in Figure 3.NOVEL POTENTIAL THERAPEUTIC
STRATEGIES
Currently, no drug strategies can prevent or reverse CAVD and
valve replacement remains the only treatment option. Patients
with severe CAVD undergo valve replacement either with
surgery or via percutaneous transcatheter procedures. Drugs
already used to treat vascular complications might alsoFrontiers in Pharmacology | www.frontiersin.org 8improve CAVD outcomes, but the mechanisms of valve
calcification differ from other vascular conditions (Hutcheson
et al., 2014).
A randomized trial of intensive lipid-lowering therapy failed to
stop ore reverse the progression of CAVD.However, the possibility
that this specific pharmacological treatment induces a small
reduction in disease progression or in the main clinical endpoints
cannot be excluded (Cowell et al., 2005; Rossebo et al., 2008). Anti-
inflammatory agents represent a promising therapeutic strategy
that requires additional research in CAVD patients (Hurle et al.,
2013). Due to the role of angiotensin II in CAVD development,
inhibitors of angiotensin-converting enzyme (ACE-I) have also
been explored. Notably, no significant difference in disease
progression was observed in a retrospective cohort of more than
200 patients. The benefits of ACE-I aremostly related to their effect
on left ventricular remodeling.
Human monoclonal antibodies have been used successfully in
many conditions. In 2015 Lerman et al. found that denosumab, a
human monoclonal antibody targeting the receptor activator of
nuclear factor-kB ligand, may reduce valvular calcium
deposition to basal levels (Lerman et al., 2015). Furthermore,
denosumab reduced calcium deposition in the aorta, although
the mechanisms by which it affected ectopic calcification, must
be further examined. (Helas et al., 2009) Nonetheless, this field
remains attractive and promising.
After GWAS and TWAS studies discovering several genes
implicated in the CAVD pathogenesis, genetic therapy could also
be a possible therapeutic development. A growing body of
experimental evidence supports the role of epigenetic factors
such as miRNAs and markers of DNA methylation, as regulators
of key processes underlying valvular tissue remodeling and
participators in the landscape of phenotypical changesFIGURE 3 | The putative interaction between the microbiome and immune response in CAVD development. Increased shear stress, genetic factors, and oxygen
reactive species cause the endothelial damage that allows ox-LDLs, immune and inflammatory cells to infiltrate the valve. Macrophages and ox-LDLs stimulate VICs
inflammation through NF-kB/IL-6 signaling pathway. The microbiome and microbial metabolites can modulate the immune system through the intense effect of
SFCAs on T cells’ differentiation. Furthermore, the bacterial metabolite TMAO can induce ox-LDL and maintain the inflammatory loop. IL-6, interleukin 6; NF-kB,
nuclear factor k-light-chain enhancer of activated B cells; ox-LDL, oxidized low-density lipoprotein; SCFA, short-chain fatty acid; TMAO-Trimethylamine-N oxide;
VECs, valve endothelial cells; VICs, vascular interstitial cells.May 2020 | Volume 11 | Article 685
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reversible, they could offer important targets for diagnostic and
therapeutic interventions.
The recently introduced, tissue-engineered heart valves
[tissue engineered heart valves (TEHVs)] may constitute a
valid alternative to traditional strategies of valve replacement.
In TEHVs, a decellularized scaffold is seeded with patient’s cells
subjected to an appropriate series of stimuli able to promote
cellular activity. TEHVs could offer the advantages of
biocompatibility and longevity, while preventing pathological
tissue responses and regurgitation. Additionally, TEHVs could
allow VICs to produce their own extracellular matrix, thus
displaying the capacity for growth and remodeling, which is
critical for pediatric patients. TEHVs can be produced from
synthetic or natural materials (Berry et al., 2010).CONCLUSIONS
Despite its high prevalence and associated mortality, there are no
drugs to prevent or cure CAVD. Therefore, the development of
new therapeutic strategies capable of counteracting the CAVD
development is crucial.
Being a multifactorial disease, CAVD is characterized by a
complex pathobiology that involves environmental and geneticFrontiers in Pharmacology | www.frontiersin.org 9factors, immune-molecular pathways, hemodynamic factors, and
shear stress, all intertwined in the systemic district. Several of the
many steps of disease progression have been clarified but some
others, like the critical switch from inflammatory-fibrotic to
osteogenic program, or the putative role of microbiota, remain
still unclear. The quickly evolving field of epigenetic regulation of
CAVD, involving especially miRNAs and lncRNAs, could offer
novel potential biomarkers for the development of new
diagnostic and therapeutic interventions. Furthermore, the
microbiome could play a role in promoting and perpetuating
CAVD by inducing the production of endogenous or exogenous
antigens via the activation of inflammatory pathways. The
elucidation of these conundrums will help identify new disease
targets, host or microbial, and support the design of new
potential therapeutic strategies to prevent or reverse the effects
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